Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Pediatr Adolesc Med. 2007 Nov;161(11):1068-74.

Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation.

Author information

  • 1Department of Family and Community Medicine, The University of Arizona College of Medicine, Tucson, AZ 85704, USA. myram@email.arizona.edu

Abstract

OBJECTIVE:

To assess the safety and efficacy of sustained-release bupropion hydrochloride for adolescent smoking cessation.

DESIGN:

Prospective, randomized, double-blind, placebo-controlled, dose-ranging trial.

SETTING:

Metropolitan areas of Tucson and Phoenix, Arizona.

PARTICIPANTS:

Adolescents (N = 312) recruited through media and various community venues from March 1, 1999, through December 31, 2002, who were aged 14 to 17 years, smoked 6 or more cigarettes per day, had an exhaled carbon monoxide level of 10 ppm or greater, had at least 2 previous quit attempts, and had no other current major psychiatric diagnosis.

INTERVENTION:

Sustained-release bupropion hydrochloride, 150 mg/d (n = 105) or 300 mg/d (n = 104), or placebo (n = 103) for 6 weeks, plus weekly brief individual counseling. Subjects were followed up at 12 weeks (by telephone call) and 26 weeks.

MAIN OUTCOME MEASURE:

Confirmed 7-day point prevalence abstinence at 6 weeks and 30-day prolonged abstinence (carbon monoxide level < 10 ppm at each visit; urinary cotinine level < or = 50 microg/L at weeks 2 and 6).

RESULTS:

Cotinine-confirmed 7-day point prevalence abstinence rates at 6 weeks were as follows: placebo, 5.6%; 150 mg, 10.7%; and 300 mg, 14.5% (P = .03, 300 mg vs placebo). At 26 weeks, confirmed point prevalence abstinence rates were as follows: placebo, 10.3%; 150 mg, 3.1%; and 300 mg, 13.9% (P = .049). During treatment, confirmed point prevalence rates were significantly higher for 300 mg than placebo at every week except week 4.

CONCLUSIONS:

Sustained-release bupropion hydrochloride, 300 mg/d, plus brief counseling demonstrated short-term efficacy for adolescent smoking cessation. Abstinence rates were lower than those reported for adults, with rapid relapse after medication discontinuation.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT00344695.

Comment in

PMID:
17984409
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk